+++ Wie lange reichen 500.000 Euro? Erfahren Sie mehr in Ihrem "Leitfaden für Ihr Alterseinkommen". Für Anleger ab 250.000 €. +++-w-
24.07.2021 15:31:00

Why Is Novo Nordisk Buying a Rare-Disease Candidate?

Novo Nordisk (NYSE: NVO) recently announced that it's buying Prothena's (NASDAQ: PRTA) transthetyrin amyloidosis (ATTR) cardiomyopathy program for up to $1.2 billion. In this Motley Fool Live video recorded on July 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why Novo, which is best known for its diabetes franchise, is buying a rare-disease drug candidate.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"